These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24728513)

  • 1. Italian risk-sharing agreements on drugs: are they worthwhile?
    Garattini L; Curto A; van de Vooren K
    Eur J Health Econ; 2015 Jan; 16(1):1-3. PubMed ID: 24728513
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

  • 3. [Innovative agreements with the pharmaceutical industry: "pay for performance"].
    Badia X; Prior M
    Farm Hosp; 2010; 34(2):53-5. PubMed ID: 20207566
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
    Triki N; Ash N; Porath A; Birnbaum Y; Greenberg D; Hammerman A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):749-753. PubMed ID: 31825682
    [No Abstract]   [Full Text] [Related]  

  • 5. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
    Barros PP
    Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory, Policy, and Operational Considerations for Outcomes-Based Risk-Sharing Agreements in the U.S. Market: Opportunities for Reform.
    Goodman C; Villarivera C; Gregor K; van Bavel J
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1174-1181. PubMed ID: 31535596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deal watch: Harnessing creative risk sharing.
    Papp T
    Nat Rev Drug Discov; 2010 Sep; 9(9):671. PubMed ID: 20811371
    [No Abstract]   [Full Text] [Related]  

  • 9. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
    Darbà J; Ascanio M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):743-748. PubMed ID: 30821532
    [No Abstract]   [Full Text] [Related]  

  • 10. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
    Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
    Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical risk-sharing agreements.
    Gandjour A
    Pharmacoeconomics; 2009; 27(5):431-2. PubMed ID: 19586080
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk sharing agreements: what lessons from Italy?
    Garattini L; Casadei G
    Int J Technol Assess Health Care; 2011 Apr; 27(2):169-72. PubMed ID: 21429288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where are we on "risk-sharing" agreements?
    Neumann PJ
    Value Health; 2013; 16(5):701-2. PubMed ID: 23947962
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contractual arrangements between HMOs and medical groups to manage drug costs.
    Curtiss FR
    J Manag Care Pharm; 2003; 9(6):572-3. PubMed ID: 14664667
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
    Ogbighele E
    IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.